Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Potential biomarkers for treatment response in advanced non-pancreatic neuroendocrine tumors.
Authors
Sahithi Sonti
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Sahithi Sonti , Katy Wang , Kristopher Attwood , Hans Minderman , Orla Maguire , Courtney Ryan , Nitika Sharma , Bhavana Konda , Renuka V. Iyer , Anuradha Krishnamurthy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 599)
DOI
10.1200/JCO.2024.42.3_suppl.599
Abstract #
599
Poster Bd #
H10
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Differential genomic and transcriptomic analysis of invasive lobular and ductal carcinomas.
First Author: Jason A Mouabbi
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Transition of the tumor microenvironment with clonal evolution of hepatocellular carcinoma.
First Author: Hiroaki Kanzaki
Poster
2024 ASCO Annual Meeting
A phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line treatment of advanced non-small cell lung cancer.
First Author: Nashat Gabrail
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in castrate-resistant prostate cancer and certain other immunologically cold tumors.
First Author: Jonathan Alexander Chatzkel